Drugs / ISIS 183750
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT01675128 | Aug 2012 → Dec 2014 | colorectal carcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ISIS 183750 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01675128 ↗ |
| Action | Inhibit | “designed to inhibit the production of the eIF4E protein” PMID 27194579 ↗ Jun 2016 |
| Modality | Antisense oligonucleotide | “ISIS 183750 is a second-generation antisense oligonucleotide (ASO)” NCT01675128 ↗ |
| Route | Intravenous | “ISIS 183750 will be administered intravenously on Cycle 1 Days 1, 3, 5, 8, 15 and 22.” NCT01675128 ↗ |
| Target | EIF4E | “designed to inhibit the production of the eIF4E protein” PMID 27194579 ↗ Jun 2016 |